Cited by 333Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementCancer Genomics and Diagnostics

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Open access

Lee, J.H., Long, G.V., Boyd, S., Lo, S., Menzies, A.M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R.A., Mann, G.J., Kefford, R.F., Carlino, M.S., Rizos, H.·2017·Annals of Oncology

DOI 10.1093/annonc/mdx026

Open this paper in CoChat — free account Open PDF

Abstract

Background Programmed death 1 (PD1) inhibitors are now a foundation of medical management of metastatic melanoma. This study sought to determine whether circulating tumour DNA (ctDNA) provides useful early response and prognostic information.Patients and methods We evaluated the relationship between pre-treatment and early on treatment ctDNA and outcome in melanoma patients treated with PD1 inhibitors alone or in combination with ipilimumab.Results ctDNA was detected in 40/76 patients (53%) at baseline, and correlated with stage, LDH levels, disease volume and ECOG performance. RECIST response was 72% (26/36) in group A (undetectable ctDNA at baseline), 77% (17/22) in group B (elevated ctDNA at baseline but undetectable within 12 weeks of therapy) and 6% (1/18) in group C (elevated ctDNA at baseline and remained elevated during treatment). The median PFS was not reached in groups A and B and was 2.7 months for group C [hazard ratio (HR) 0.09; P < 0.001 for group A versus C, and 0.16; P < 0.001 for group B versus C]. The median OS was not reached for groups A and B and was 9.2 months for group C (HR 0.02; P < 0.001 for group A versus C and 0.14; P < 0.001 for group B versus C). The poor outcome measures associated with group C remained significant in multivariate analysis adjusted for LDH, performance status, tumour stage and disease volume. The predictive value for ctDNA for response was confirmed in a separate validation cohort (n = 29, P < 0.01).Conclusion Longitudinal assessment of ctDNA in metastatic melanoma patients receiving treatment with PD1 inhibitors is an accurate predictor of tumour response, PFS and OS. Patients who had a persistently elevated ctDNA on therapy had a poor prognosis, and this may guide combination and sequencing of subsequent therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx026

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citation
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citation
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,590
Absolute quantification by droplet digital PCR versus analog real-time PCR
Hindson, C. M., Chevillet, J. R., Briggs, H. A., Gallichotte, E. N., Ruf, I. K., Hindson, B. J., Vessella, R. L., & Tewari, M. (2013) · Nature Methods · doi:10.1038/nmeth.2633 · Cited by 1,488

Flagged first, then by citations

Show all 25 references

2 of the 25 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 333

Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma
Mourah, S., Louveau, B., & Dumaz, N. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000603 · Cited by 12
Overview of Basic Immunology and Clinical Application
Stephen, B., & Hajjar, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_1 · Cited by 11
Supercharged NK Cell-Based Immuotherapy in Humanized Bone Marrow Liver and Thymus (Hu-BLT) Mice Model of Oral, Pancreatic, Glioblastoma, Hepatic, Melanoma and Ovarian Cancers
Kaur, K., & Jewett, A. (2023) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2023050618 · Cited by 10
Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re‐radiotherapy
Janke, F., Stritzke, F., Dvornikovich, K., Franke, H., Angeles, A. K., Riediger, A. L., Ogrodnik, S. J., Gerhardt, S., Regnery, S., Schröter, P., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35152 · Cited by 10
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
Guardo, L. D., Randon, G., Corti, F., Vallacchi, V., Raimondi, A., Fucà, G., Bini, M., Maurichi, A., Patuzzo, R., Gallino, G., et al. (2021) · The Oncologist · doi:10.1002/onco.13926 · Cited by 10
Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios
Khaddour, K., Zhou, A. Y., Butt, O. H., Budde, G. L., Malashevich, A. K., & Ansstas, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.978996 · Cited by 10
PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
Gabryś, H., Basler, L., Burgermeister, S., Hogan, S., Ahmadsei, M., Pavic, M., Bogowicz, M., Vuong, D., Tanadini-Lang, S., Förster, R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.977822 · Cited by 11
The Role of Biomarkers in the Diagnosis and Prognosis of Different Stages of Melanoma
Nwafor, J. N., Torere, B. E., Agu, E., Kadiku, L., Ogunyemi, T., Akinsanya, P. A., Araromi, O. O., Akahara, D. E., & Okobi, O. E. (2023) · Cureus · doi:10.7759/cureus.38693 · Cited by 10
Methylated Circulating Tumor DNA as a Biomarker in Cutaneous Melanoma
Diefenbach, R. J., Lee, J., & Rizos, H. (2020) · Melanoma Management · doi:10.2217/mmt-2020-0010 · Cited by 10
Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer
Sakatani, T., Sumiyoshi, T., Kita, Y., Takada, H., Nakamura, K. D., Hamada, A., Murakami, K., Sano, T., Goto, T., Sawada, A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00472 · Cited by 9
Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies
Catani, G., Morchón-Araujo, D., Mirallas, O., Sánchez-Pérez, V., Nuciforo, P. G., Villacampa, G. J., Dienstmann, R., Vivancos, A. P., Garralda, E., & Hernando‐Calvo, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664443 · Cited by 9
Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma
Ashida, A., Sakaizawa, K., Mikoshiba, A., Kiniwa, Y., & Okuyama, R. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3279 · Cited by 9
Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions
Liu, Z., Han, Y., Dang, Q., Xu, H., Zhang, Y., Duo, M., Lv, J., Li, H., Kong, Y., & Han, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109173 · Cited by 9
Hyperprogression in Advanced Melanoma is Not Restricted to Immunotherapy
Fournier, M., Mortier, L., Dereure, O., Dalac, S., Oriano, B., Dalle, S., & Lebbé, C. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113289 · Cited by 9
Gene Expression Profiling in Melanoma: Past Results and Future Potential
Knackstedt, R. W., Knackstedt, T., & Gastman, B. (2018) · Future Oncology · doi:10.2217/fon-2018-0631 · Cited by 9
Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
Stagno, A. M., Vari, S., Annovazzi, A., Anelli, V., Russillo, M., Cognetti, F., & Ferraresi, V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645008 · Cited by 9
Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma
Tolmeijer, S. H., Koornstra, R. H. T., de Groot, J. W. B., Geerlings, M. J., van Rens, D. H., Boers‐Sonderen, M. J., Schalken, J. A., Gerritsen, W. R., Ligtenberg, M. J. L., & Mehra, N. (2021) · Cancers · doi:10.3390/cancers13153913 · Cited by 9
Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma
Rozeman, E. A., Versluis, J. M., Moritz, R., Wilgenhof, S., van Thienen, J. V., Haanen, J. B. A. G., van den Heuvel, M. M., Blank, C. U., & van Rossum, H. H. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.06.001 · Cited by 10
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
Hepner, A., Versluis, J. M., Wallace, R., Allayous, C., Brown, L. J., Trojaniello, C., Gerard, C. L., Jansen, Y. J., Bhave, P., Neyns, B., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113441 · Cited by 8
Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)
Martines, G., Carolina, P., Gregorio, M. J. C., Verzè, M., Pluchino, M., Claire, G. G., Michele, M., Giulia, M., Manuguerra, R., Azzoni, C., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100295 · Cited by 10
Effect of neoadjuvant therapy on survival outcomes in patients with melanoma: a systematic review and meta-analysis
Yuan, F., Jing, M., Chen, X., & Zhang, X. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103504 · Cited by 9
Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
Fitzgerald, S. J., Blenkiron, C., Stephens, R., Mathy, J. A., Somers‐Edgar, T. J., Rolfe, G., Martin, R., Jackson, C., Eccles, M. R., Robb, T. J., et al. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00651-4 · Cited by 8
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
Smithy, J. W., Kalvin, H. L., Ehrich, F. D., Shah, R. H., Adamow, M. J., Raber, V., Maher, C. A., Kleman, J., McIntyre, D. A. G., Shoushtari, A. N., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3643 · Cited by 8
Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead
Hita-Millan, J., Carracedo, Á., & Fernández–Rozadilla, C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11100971 · Cited by 8
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Maansson, C. T., Nielsen, A. L., & Sørensen, B. S. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70145 · Cited by 13
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Garralda, E., Abbott, C. W., Calahorro, A., Mirallas, O., Pugh, J. L., Moreno-Cárdenas, A. B., Keough, K. C., Galvao, V., Alonso, G., Olano, A. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2312 · Cited by 7
Current advances in kidney cancer immunotherapy
Коротаева, А. А., Apanovich, N. V., Александровна, Б. Э., Matveev, V. B., & Karpukhin, A. V. (2019) · Cancer Urology · doi:10.17650/1726-9776-2019-15-4-30-38 · Cited by 7
When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?
Banks, L. B., & Sullivan, R. J. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00506-2 · Cited by 7
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)
Ascierto, P. A., Puzanov, I. J., Agarwala, S. S., Blank, C. U., Carvajal, R. D., Demaria, S., Dummer, R., Ernstoff, M. S., Ferrone, S., Fox, B. A., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02482-x · Cited by 7
Novel Biomarkers and Druggable Targets in Advanced Melanoma
Ferrucci, P. F., & Cocorocchio, E. (2021) · Cancers · doi:10.3390/cancers14010081 · Cited by 7
Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients
Warburton, L., Reid, A. L., Amanuel, B., Calapre, L., Millward, M., & Gray, E. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1280730 · Cited by 7
Overview of Basic Immunology and Translational Relevance for Clinical Investigators
Stephen, B., & Hajjar, J. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_1 · Cited by 7
Use of Circulating Tumoral DNA to Guide Treatment for Metastatic Melanoma
Herbreteau, G., Charpentier, S., Vallée, A., & Denis, M. G. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0097 · Cited by 7
Hypermethylation of Circulating Free DNA in Cutaneous Melanoma
Diefenbach, R. J., Lee, J., Chandler, D., Wang, Y., Pflueger, C., Long, G. V., Scolyer, R. A., Carlino, M. S., Menzies, A. M., Kefford, R. F., et al. (2019) · Applied Sciences · doi:10.3390/app9235074 · Cited by 7
US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma
Fischer, R. A., Ryan, I., Torre, K. D. L., Barnett, C., Sehgal, V. S., Levy, J. B., Luke, J. J., Poklepovic, A. S., & Hurlbert, M. S. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104289 · Cited by 6
Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients
Emelyanova, M., Телышева, Е. Н., Орлова, К. В., Ryabaya, O. O., Snigiryova, G. P., Abramov, I. S., & Mikhailovich, V. M. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.11.005 · Cited by 6
Tissue-Based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma
Gide, T. N., Mao, Y., Scolyer, R. A., Long, G. V., & Wilmott, J. S. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1109 · Cited by 7
Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations
Raja, R. G., Lee, Y. S., Streicher, K. L., Conway, J., Wu, S., Sridhar, S., Kuziora, M., Liu, H., Higgs, B. W., Brohawn, P. Z., et al. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0192-8 · Cited by 5
The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report
Wang, Z., Ye, C.-Y., Zhou, W., Wang, M., Dai, W.-P., Zheng, J., & Zang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s265725 · Cited by 5
Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
Diefenbach, R. J., Lee, J., Stewart, A., Menzies, A. M., Carlino, M. S., Saw, R. P. M., Stretch, J. R., Long, G. V., Scolyer, R. A., & Rizos, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.820510 · Cited by 5
Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis
Kayashima, A., Shimozaki, K., Hirata, K., Mutaguchi, M., Takabayashi, K., Hayashi, Y., Hosoe, N., Ogata, H., Sujino, T., & Kanai∥, T. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01261-x · Cited by 5
Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma
Martínez-Vila, C., Teixidó, C., Martín, R., Aya, F., Sudhaman, S., Budde, G. L., González‐Navarro, E. A., Alós, L., de Anta, N. C., Ortiz, J. B., et al. (2025) · Cancers · doi:10.3390/cancers17233804 · Cited by 4
Toward Personalized Response Monitoring in Melanoma Patients Treated with Immunotherapy and Target Therapy
Venturi, F., Magnaterra, E., Gualandi, A., Scotti, B., Baraldi, C., Alessandrini, A. M., Veneziano, L., Cama, E. M., Melotti, B., Marchese, P. V., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15233054 · Cited by 6
Chromosomal Instability in Cell-free DNA as a Prognostic Biomarker of Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy
Lee, C. U., Cho, E., Lee, J., Lim, J. E., Chung, J. H., Song, W., Kang, M., Sung, H. H., Jeong, B. C., Seo, S. I., et al. (2022) · European Urology Focus · doi:10.1016/j.euf.2022.09.002 · Cited by 4
Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor
Mattila, K., Mäkelä, S., Kytölä, S. I., Andersson, E. I., Vihinen, P., Ramadan, S., Skyttä, T., Tiainen, L., Vuoristo, M., Tyynelä-Korhonen, K., et al. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2137693 · Cited by 4
Computational Modeling for Circulating Cell-Free DNA in Clinical Oncology
Phuong, L. N., Salas, S., & Benzekry, S. (2025) · JCO Clinical Cancer Informatics · doi:10.1200/cci-24-00224 · Cited by 4
Circulating biomarkers of response to immunotherapy and immune-related adverse events
Garrison, Z. R., Hornick, N. I., Cheng, J. B., & Kulkarni, R. P. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2130688 · Cited by 4
Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers
Liu, D., Hu, L., & Shao, H. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04541-8 · Cited by 4
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy
Asher, N., Bar-Hai, N., Ben‐Betzalel, G., Stoff, R., Grynberg, S., Schachter, J., Steinberg‐Silman, Y., Gelernter, L., Shlasky, A., & Frommer-Shapira, R. (2024) · Melanoma Research · doi:10.1097/cmr.0000000000000985 · Cited by 4
Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives
Alrabadi, N., Haddad, R. H., & Alomari, A. K. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0708-4 · Cited by 4
Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study
Berger, M., Thueringer, A., Franz, D., Dandachi, N., Talakić, E., Richtig, G., Richtig, E., Rohrer, P. M., Koch, L., Wolf, I. H., et al. (2021) · Cancers · doi:10.3390/cancers13123101 · Cited by 4
Early assessment of molecular progression and response by whole-genome circulating tumor DNA in advanced solid tumorsPreprint
Davis, A. A., Iams, W. T., Chan, D., Oh, M. S., Lentz, R. W., Peterman, N., Robertson, A., Shah, A., Srivas, R., Wilson, T., et al. (2019) · medRxiv · doi:10.1101/19002550 · Cited by 4
Translating ctDNA into cutaneous melanoma care: An international expert survey
Geidel, G., Fekade, N., Raabe, K., Smit, D. J., Adam, L., Heidrich, I., Rünger, A., Kött, J., Zell, T., Amaral, T., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116676 · Cited by 3
Circulating tumor DNA for surveillance in high-risk melanoma patients: a study protocol
Obinah, M. P. B., Al-Halafi, S. A., Dreisig, K., Poulsen, T. S., Johansen, C., Litman, T., Bojesen, S. E., Høgdall, E. V. S., Chakera, A. H., & Hölmich, L. R. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.42515 · Cited by 3
Scientific rationale for immunotherapy in lymphoma and predictors of response
Karmali, R., Sosman, J. A., & Gordon, L. I. (2017) · Annals of Lymphoma · doi:10.21037/aol.2017.11.02 · Cited by 3
Impact of genomics on the surgical management of melanoma
Ferguson, P. M., Long, G. V., Scolyer, R. A., & Thompson, J. F. (2018) · British journal of surgery · doi:10.1002/bjs.10751 · Cited by 3
Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy
Welsh, S. J., & Corrie, P. G. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3497 · Cited by 3
Biomarkers in metastatic melanoma of the skin: can we more accurately choose the tactics of treating our patients?
Zaretsky, A. R., Демидов, Л. В., & Самойленко, И. В. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-9-48-63 · Cited by 4
Pre-Amplification of Cell-Free DNA: Balancing Amplification Errors with Enhanced Sensitivity
Chan, W. Y., Stewart, A., Diefenbach, R. J., Gray, E. S., Lee, J., Scolyer, R. A., Long, G. V., & Rizos, H. (2025) · Biomolecules · doi:10.3390/biom15060883 · Cited by 3
Plasma Methylated DNA Markers for Melanoma Surveillance
Berger, C. K., Taylor, W. R., Mahoney, D. W., Burger, K. N., Doering, K. A., Gonser, A. M., Cao, X., Heilberger, J., Gysbers, B. J., Foote, P. H., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00389 · Cited by 2
How I Treat Non–Small Cell Lung Cancer Refractory to Immunotherapy
Wong, S. K., & Horn, L. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000482 · Cited by 2
Systematic literature Review for the Association of Biomarkers with Efficacy of Anti-PD-1 Inhibitors in Advanced Melanoma
Scherrer, E., Rau, R., Lorenzi, M. F., Shui, I. M., Townson, S. M., & Larkin, J. (2021) · Future Oncology · doi:10.2217/fon-2021-0154 · Cited by 2
Pseudoprogression during Successful Rechallenge of Immune Checkpoint Inhibitor in a NSCLC Patient
Kagohashi, K., Miyazaki, K., Shiozawa, T., & Satoh, H. (2021) · Advances in respiratory medicine · doi:10.5603/arm.a2021.0016 · Cited by 2
Immune System in Action
Stephen, B., & Hajjar, J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_1 · Cited by 2
Immune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2
Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care
Tu, S., Trikannad, A. K., Vellanki, S., Hussain, M., Malik, N., Singh, S. R. K., Jillella, A., Obulareddy, S. J., Malapati, S. J., Bhatti, S. A., et al. (2024) · Cancers · doi:10.3390/cancers16061151 · Cited by 3
Novel Methods to Overcome Acquired Resistance to Immunotherapy
Zhao, X., Yuan, C., Rieth, J. M., Wangmo, D., & Subramanian, S. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_4 · Cited by 2
Biopsia líquida en oncología: Consenso de la Sociedad Española de Oncología Médica (SEOM) y la Sociedad Española de Anatomía Patológica (SEAP)
Álvarez-Alegret, R., Rojo, F., Garrido, P., Bellosillo, B., Rodríguez-Lescure, Á., Rodríguez‐Peralto, J. L., Vera, R., de Álava, E., García‐Campelo, R., & Remón, J. (2020) · Revista Española de Patología · doi:10.1016/j.patol.2019.12.001 · Cited by 1
A Perspective: The Integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for Phase II Immunotherapy Clinical Trials
Kuş, T., & Çiçin, İ. (2024) · Immunotherapy · doi:10.2217/imt-2023-0184 · Cited by 1
Metabolomics-based biomarkers of probiotic efficacy in toxicological settings
Emegano, D. I., Battal, D., & Kocadal, K. (2024) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-024-00546-1 · Cited by 2
Biomarker analysis of circulating tumor DNA in clinical stage III melanoma patients treated with neoadjuvant immunotherapy combined with targeted therapy
Stoff, R., Routman, D. M., Yalon, M., Bogan, A. W., Block, M. S., & Hieken, T. J. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251412729 · Cited by 1
Surgical Management of Stage IV Melanoma: Clinical, Molecular, and Therapeutic Considerations
Uche, I. K., & Lyons, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052327 · Cited by 1
Requiring Caution in the Interpretation of Donor‐Derived Cell‐Free DNA Levels During Cancer Treatment in a Kidney Transplant Recipient.: A Case Report
Katsurayama, N., Hirai, T., Kijima, Y., Ishihara, H., Fukuda, H., Omoto, K., Shimizu, T., Inui, M., Ishida, H., & Takagi, T. (2026) · IJU Case Reports · doi:10.1002/iju5.70180 · Cited by 1
Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features
Fountoukidis, G., Tina, E., Eremo, A. G., Ullenhag, G. J., & Valachis, A. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04433-9 · Cited by 1
Reshaping the Battlefield: Reprogramming the Melanoma Tumour Microenvironment (TME) by Anti-CTLA-4, Anti-PD-1, and Anti-PD-L1 Monotherapy and Combination Therapy: A Systematic Review and Meta-Analysis of Preclinical and Clinical Evidence
Karakousis, V. A., Mantalovas, S., Karakousi, V. C., Vizirianakis, I. S., Papamitsou, T., Pavlidis, L., & Kosmidis, C. S. (2026) · Cells · doi:10.3390/cells15131182 · Cited by 1
Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy
Heidrich, I., Urhahn, S., Gebhardt, C., Smit, D. J., & Pantel, K. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01056-9 · Cited by 1
Timing matters: how mechanism-guided sequencing shapes the efficacy of radiotherapy-immunotherapy combinations
Cattaneo, C. G., Pozzo, E., Panza, G., Chiloiro, G., Romano, A., Galetto, M., Nardini, M., Placidi, L., Gambacorta, M. A., & Boldrini, L. (2026) · Strahlentherapie und Onkologie · doi:10.1007/s00066-026-02570-9 · Cited by 1
Biomarkers for Melanoma
Schadendorf, D., Flaherty, K. T., Duncan, L. M., Kashani–Sabet, M., & Ugurel, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_45 · Cited by 1
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)
Ascierto, P. A., Blank, C. U., Dummer, R., Ernstoff, M. S., Ferrone, S., Fox, B. A., Gajewski, T. F., Garbe, C., Hwu, P., Kaliński, P., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02951-x · Cited by 1
Predictive Biomarkers of Melanoma
Hanly, A. M., Gibson, F. T., & Alani, R. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82639-0_16 · Cited by 1
Droplet Digital PCR: An Emerging Technology for Cutaneous Melanoma Detection and Monitoring
Dobre, E.-G., & Neagu, M. T. (2021) · International Electronic Conference on Biomedicine (ECB) · doi:10.3390/ecb2021-10280 · Cited by 1
Current Advances in Immune Checkpoint Therapy
Russell, B. L., Malindisa, S. T., Sooklal, S. A., & Ntwasa, M. M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.107315 · Cited by 1
"Correlation between Serum Interleukin-8, Interleukin-6 Levels, and the Response to Anti-PD-1/PD-L1 Inhibitor in Patients with Malignant Tumors: A Prospective Observational Study"
Tang, X. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.53.008349 · Cited by 1
The implementation of liquid biopsies in routine care of patients with advanced solid cancer (LIQPLAT): a study protocol for a single arm trialPreprint
Schwenke, J. M., Schmitt, A. M., Janiaud, P., Läubli, H., Binder, M., Alborelli, I., Matter, M. S., Hinke, J., Widmer, C. C., Hemkens, L. G., et al. (2025) · medRxiv · doi:10.1101/2025.02.13.25322206 · Cited by 1
Molecular Pathway and Fluorescence In Situ Hybridization Testing of ERBB2 (HER2) Gene Amplification in Invasive Ductal Carcinoma of Breast
Jodlowski, T., & Ramesh, K. H. (2019) · Springer eBooks · doi:10.1007/978-981-13-5877-7_15
Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy
Pinho, A. V., Lee, J., & Rizos, H. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_8
The Laboratory Evaluation of Melanoma
Lullo, J. J., & Shitabata, P. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-27400-9_3
Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies
Uhlig, J., Biggemann, L., Sheth, A. H., & Sharma, R. (2020) · Digestive Disease Interventions · doi:10.1055/s-0040-1721404
Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients
Marsavela, G., Reid, A. L., Gray, E. S., & Calapre, L. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1205-7_19
Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings
Castello, A., & Lopci, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-68858-5_8
Therapeutic Intervention in Skin Cancer: Future Prospects
Srivastava, R. (2021) · Springer eBooks · doi:10.1007/978-981-16-0364-8_2
Biomarkers for Melanoma
Schadendorf, D., Flaherty, K. T., Duncan, L. M., Kashani–Sabet, M., & Ugurel, S. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_45-1
Clinical utility of analyzing circulating tumor DNA in patients with non-small cell lung carcinomaPreprint
Jiang, H., Zhang, Y., Zhang, L., Kuang, Y., Li, J., & Sui, N. (2022) · Research Square · doi:10.21203/rs.3.rs-1519425/v1
Personalized circulating tumor DNA detection for monitoring immunotherapy efficacy in locally advanced or metastatic non-small cell lung cancerPreprint
Cheng, L., Gao, G., Zhao, C., Wang, H., Yao, C. L., Yu, H., Yao, J., Li, F., Guo, L., Jian, Q., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2357859/v1
Liquid biopsy and immunotherapy: is all that glitter gold?
Incorvaia, L., Perez, A., Brando, C., Gristina, V., Mantia, M. L., Castiglia, M., Fanale, D., Galvano, A., Badalamenti, G., Russo, A. D., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822703-9.00005-3
Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma
Bobak, K., Synoradzki, K. J., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_179-1
Immune Checkpoint Blockade Response Biomarkers
Garrido-Barros, M., Cháves, P., & Barragán, I. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_160-1
Table S1 from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Basler, L., Gabryś, H. S., Hogan, S. A., Pavic, M., Bogowicz, M., Vuong, D., Tanadini‐Lang, S., Forster, R. E., Kudura, K., Huellner, M. W., et al. (2023) · doi:10.1158/1078-0432.22478060.v1
Data from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Basler, L., Gabryś, H. S., Hogan, S. A., Pavic, M., Bogowicz, M., Vuong, D., Tanadini‐Lang, S., Forster, R. E., Kudura, K., Huellner, M. W., et al. (2023) · doi:10.1158/1078-0432.c.6529838.v1
ctDNA-Analysen beim Melanom im adjuvanten und palliativen Stadium: Starker prognostischer Biomarker
Heidrich, I., & Gebhardt, C. (2023) · Trillium Diagnostik · doi:10.47184/td.2023.03.06

Authors: Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., Kefford, R. F., Carlino, M. S., & Rizos, H.
Affiliations: The University of Sydney (AU)
Macquarie University (AU)
Melanoma Institute Australia (AU)
Royal Prince Alfred Hospital (AU)
Corresponding author: Rizos, H.
ORCID: Lee, J.H.
Long, G.V.
Lo, S.
Menzies, A.M.
Guminski, A.
Jakrot, V.
Scolyer, R.A.
Mann, G.J.
Kefford, R.F.
Carlino, M.S.
Rizos, H.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2017-05
Volume: 28
Issue: 5
Pages: 1130-1136
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdx026
OpenAlex: W2588078993
Cited by: 333
References: 25
Citations by year: 2026: 22 · 2025: 21 · 2024: 16 · 2023: 52 · 2022: 28 · 2021: 51 · 2020: 48 · 2019: 43 · 2018: 39 · 2017: 12
FWCI: 17.23
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 917 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Health and Medical Research Council (1093017 and 1130423)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: circulating tumor DNA, metastatic melanoma, PD-1 inhibitors, ipilimumab, treatment response prediction, prognostic factors, progression-free survival, overall survival, longitudinal ctDNA monitoring, immune checkpoint inhibitors
MeSH terms: Circulating Tumor DNA, Ipilimumab, Aged, Antibodies, Anti-Idiotypic, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Biomarkers, Tumor, Neoplasms, Second Primary, Disease-Free Survival, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks